Expanded Access to Cancer Treatments From Conversion to Neutropenia Prophylaxis With Biosimilar Filgrastim-SNDZ

Future Oncology - United Kingdom
doi 10.2217/fon-2017-0374
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Expanded Access to Pembrolizumab From Cost-Savings Generated by Biosimilar Filgrastim (BIOSIM-FIL) in the Prophylaxis of Chemotherapy-Induced (FEBRILE) Neutropenia (CIN/FN): Simulation Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Pcn32 - The Effectiveness and Safety of Switching From Orginal Filgrastim to Biosimilar Filgrastim in Primary Prophylaxis of Chemotherapy Induced Febrile Neutropenia: A Retrospective Cohort Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Filgrastim-SNDZ Debuts as the First Biosimilar Approved in United States

Journal of Community and Supportive Oncology
OncologyHematology
2015English

Pharmacokinetic Profiles of a Biosimilar Filgrastim and Amgen Filgrastim: Results From a Randomized, Phase I Trial

Annals of Hematology
MedicineHematology
2010English

Filgrastim Therapy in a Child With Neutropenia Induced by Linezolid

International Journal of Clinical Pharmacy
ToxicologyPharmacyPharmacologyPharmaceutical Science
2013English

Quality Comparison of Biosimilar and Copy Filgrastim Products With the Innovator Product

Pharmaceutical Research
Organic ChemistryBiotechnologyMolecular MedicinePharmacologyPharmaceutical Science
2018English

Comparison of the Pharmacodynamic Profiles of a Biosimilar Filgrastim and Amgen Filgrastim: Results From a Randomized, Phase I Trial

Annals of Hematology
MedicineHematology
2010English

FDA Approves First Biosimilar to Treat Cancer

Cancer Discovery
Oncology
2017English

Obstacles to Affordable Cancer Treatments

North Carolina Medical Journal
Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy